Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Cancer risk among participants in the women's interagency HIV study
Nancy A. Hessol
, Eric C. Seaberg
, Susan Preston-Martin
, L. Stewart Massad
, Henry S. Sacks
, Sylvia Silver
, Sandra Melnick
, Ovadia Abulafia
, Alexandra M. Levine
Division of Gynecologic Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
85
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cancer risk among participants in the women's interagency HIV study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Risk
100%
Women's Interagency HIV Study
100%
HIV-infected Patients
100%
Standardized Incidence Ratio
72%
Highly Active Antiretroviral Therapy (HAART)
27%
Non-Hodgkin Lymphoma
27%
Surveillance Epidemiology
27%
Increased Incidence
18%
Incidence Rate
18%
United States
9%
Cancer Types
9%
Relative Risk
9%
Cancer Screening
9%
Lung Cancer
9%
Statistical Test
9%
Cancer Prevention
9%
Population-based
9%
US Population
9%
At-risk
9%
All Cancer
9%
Kaposi Sarcoma
9%
Female Cancer
9%
Prevention Efforts
9%
Cancer Incidence Data
9%
Screening Effort
9%
HIV Epidemic
9%
State Surveillance
9%
HIV Seroconversion
9%
Increased Life Expectancy
9%
Lung Cancer Incidence
9%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Standardized Incidence Ratio
53%
Highly Active Antiretroviral Therapy
20%
Cancer
20%
Non-Hodgkin Lymphoma
20%
Surveillance, Epidemiology, and End Results
20%
Malignant Neoplasm
13%
Lung Cancer
13%
Cancer Incidence
13%
Cancer Types
6%
Cancer Prevention
6%
Study Participant
6%
Kaposi Sarcoma
6%
Life Expectancy
6%
Human Immunodeficiency Virus Risk Behavior
6%
Cancer Screening
6%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Standardized Incidence Ratio
50%
Malignant Neoplasm
25%
Nonhodgkin Lymphoma
18%
Epidemiology
18%
Cancer Incidence
12%
Lung Cancer
12%
Kaposi Sarcoma
6%
Life Expectancy
6%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Standardized Incidence Ratio
50%
Cohort Effect
18%
Epidemiology
18%
Cancer Incidence
12%
Lung
12%
Life Expectancy
6%
Cancer Screening
6%